Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

May 8, 2025

NASDAQ US Health Care Life Sciences Tools and Services earnings 59 min

Earnings Call Speaker Segments

Brian Blanchett

executive
#1

Good day, everyone, and thank you for joining Illumina's call for the first quarter of 2025 to discuss earnings. We'll go over the financial results that came out after the market closed today, share some remarks, and then take your questions. You can find our earnings release on illumina.com under Investor Relations. With us today are Jacob Thaysen, our Chief Executive Officer, and Ankur Dhingra, our Chief Financial Officer. Jacob is going to give an update on the business at Illumina, and after that Ankur will walk through the financials. Everything financial we discuss on this call pertains to core Illumina. If you want historical consolidated financials, please look at our earnings release and SEC filings. One more thing to keep in mind: any time we reference how much revenue has grown while delivering our prepared remarks, those figures are stated on a constant currency basis — in other words, they leave out the effects of foreign exchange movements. We'd suggest you review the GAAP reconciliation covering our non-GAAP measures, which you'll find in today's release as well as in the supplementary data posted on our website. Please be aware that this call is being recorded, and a recording will be made available in the Investors section of our site. Regarding any forward-looking statements about financial results and commercial activity that we make on today's call, it is our intention that all of them receive protection under the Private Securities Litigation Reform Act of 1995. To get a clearer picture of the risks and uncertainties that might make actual results come in differently, we point you toward the filings Illumina makes with the Securities and Exchange Commission, which include our latest Forms 10-Q and 10-K. Having said that, I'll hand things over now to Jacob.

Jacob Thaysen

executive
#2

Thanks, Brian, and good afternoon to all of you. Prior to starting, I'd like to pause and acknowledge Steve McMillan, our former Chair of the Board of Directors, for the way he led the effort to strengthen Illumina's standing in genomics innovation. Because of what he has done, we are well positioned for the substantial opportunities that lie ahead. I'm eager to collaborate closely with Scott Gottlieb, our new Chair, as we push our mission forward, carry out our strategy and move the omics ecosystem ahead. It's also a pleasure to welcome Keith Meister to the Board. His extensive investor background in genomics and his impressive record of creating shareholder value will prove extremely valuable as we continue building momentum and fulfilling our strategic priorities. Even with the macroeconomic difficulties of the last few months, the year got off to a solid start. Owing to the Illumina team's ongoing commitment to execution and operational excellence, our Q1 revenue and EPS landed at the top of our guidance range. Illumina is a resilient franchise with numerous drivers of near- and long-term growth, and this quarter offers plenty of reasons for encouragement. Our NovaSeq X instruments keep performing strongly, surpassing what we expected with yet another quarter of more than 60 placements in Q1, after over 90 placements in Q4. The X transition keeps moving along nicely, especially with clinical customers, confirming both the value we deliver and the durability of the clinical markets. We also recorded a sequential rise in X and overall high throughput consumables, an obvious sign that this crucial growth driver keeps building traction and showing elasticity. No one matches our innovation pipeline. We are moving the multi-omics ecosystem forward. And each day, our technologies let customers produce insights that simply weren't possible before. With that as our foundation, we concentrated on hitting our long-term financial goals. We keep carrying out our strategy of achieving high single-digit revenue growth and 500 basis point margin expenses by 2027, leaving out our Greater China region, which the recent regulatory developments have impacted. Simultaneously, we are steering through a dynamic environment with discipline and urgency. China-related developments, U.S. funding uncertainty and global trade dynamics have brought new pressures to bear on our customers. These matter, and we are taking decisive steps to deal with them. Yet these challenges are transitory and will not determine Illumina's long-term success or our leadership in driving the genomics revolution forward. Given all this, we are updating our guidance to capture both the headwinds and the proactive measures we're taking to safeguard earnings. I'll now go through each of these factors, and Ankur will share further detail in his remarks shortly. In China, restrictions now apply to our ability to export sequencing instruments. We expect reduced revenue from that region in 2025, caused by minimal instrument placements. To give greater clarity regarding the fundamentals of our global business, we will release separate guidance for the Greater China region and the rest of the world until this situation gets resolved. We remain in active dialogue with regulators in China and are exploring possible paths that would allow us to maintain a durable, long-term position in that market. As things develop, we'll share updates on any significant news. Turning to the U.S., persistent ambiguity around research funding is pressuring our customers and shifting when they make purchases. Our teams are partnering closely with those customers, providing adaptable options so their research can keep moving forward and genomic innovation can continue to advance. Back in March, we moved decisively to counter the effects of both China and the research climate, putting in place a worldwide program to cut an additional $100 million in costs. By the time of this call, all required steps have been taken so that the entire amount of savings will be captured in 2025, which reflects how rigorously we manage operations. Since we last spoke, the U.S. government has put into effect a 10% baseline tariff on imports, with much steeper rates applying to select nations. Illumina is seeing its costs rise because of these tariffs. In response, our teams are working hard to limit the damage via supply chain optimization, cost measures and pricing actions. With those steps already moving, we anticipate covering part of the effect during 2025, and assuming today's levels hold, we intend to offset it more completely in 2026. Everyone at Illumina is handling these outside pressures with care and strategy, making sure our foundational business, our dedication to customers, and our push to drive innovation stay robust and untouched; we've achieved meaningful strides in bringing forward competitively distinctive innovations that keep those customers leading the way in discovery. Our multiomics road map — an expanding set of omics and sequencing applications — is essential for growing the ecosystem and for helping us hit our long-range goals. Let me offer several illustrations. During February, we unveiled our new special offering, which delivers a substantially bigger capture area, finer resolution and heightened sensitivity compared with technologies available today. This potent solution lets researchers examine millions of cells per experiments, boosting the odds of finding rare cell populations. Such strides create fresh opportunities for research uses that simply weren't possible before. This offering will plug smoothly into Illumina's end-to-end workflows and link up with Illumina-connected multiomics, our new territory analysis solution powered by Partek's intuitive data visualization technology. Early access has started, and initial customer reactions have been highly favorable, highlighting how our spatial solutions can be accessed without buying specialized equipment and how they simplify what used to be a complicated analysis and interpretation process. We intend to launch our new spatial offering during 2026. Also connected to our multiomics strategy, we recently introduced a new single cell offering aimed at CRISPR research, with uses in oncology, immunology and drug target discovery. Our new Perturb-Seq solution will let researchers examine how genetic changes impact single cells at scale, speeding up drug discovery and deepening our grasp of complex diseases. This represents the next step forward for Fluent's PIPseq technology, which we bought last year by capturing both CRISPR, guide RNA and messenger RNA transcript from the same cell. With our offering, researchers will be able to run genome-wide CRISPR screens at costs that lead the market, giving them richer insights and better efficiency. We expect this to become available later in the current year. On top of that, our pipeline of innovations is progressing as planned. The proteomics offering we built alongside standard bio tools is in early access, and we anticipate its commercial release during the first half of 2025. Constellation mapped reads along with our 5 based genome technologies have already entered early access, with full commercial rollouts still slated for 2026; these advances have us enthusiastic as they push multiomics forward while giving our customers deeper insight than at any point before. Illumina's foundation is solid, and our projections for growth outside China remain on course as we execute our strategy. I'll hand it to Ankur now to walk through further specifics regarding our results and our 2025 outlook, and from there we'll move straight into Q&A.

Ankur Dhingra

executive
#3

Thanks, Jacob, and hello to everyone this afternoon. My plan is to walk you through the first quarter's financial results, add some detail on revenue, expenses, earnings, and what's happening on our balance sheet, and then discuss what we expect looking ahead. Before diving into the specifics of how we performed financially, I want to give you a big-picture sense of how Q1 came in versus what we had anticipated. During the first quarter, even with a fast-moving environment, the Illumina team executed extremely well, which let us land near the upper end of our guidance. Revenue came in flat compared with a year earlier, at the top end of what we had guided, and EPS of $0.97 likewise sat near the upper end of the range. Let me now take you through the financial details. Q1 revenue totaled $1.04 billion, a decline of 1.4% versus the prior-year period on an as-reported basis; that figure absorbed 1.2 points of foreign exchange headwind, while constant currency revenue was essentially flat. If you set China aside, revenue edged up slightly from a year ago in constant currency terms. Sequencing consumables brought in $696 million, up roughly 1% from the same period last year, powered by momentum in high-throughput consumables and the ongoing shift of high throughput sequencing onto X. Through the back half of the quarter, in a pattern tied to uncertainty surrounding NIH and other research funding levels, we began noticing customers — particularly those in research and academia — pulling back somewhat on consumables purchases. Our estimate is that this dynamic trimmed roughly 1 point from consumables growth versus a year ago. Even so, sequencing activity across our connected instruments stayed robust. Q1 usually brings a seasonal pickup in ordering activity, including long-range purchase commitments that build backlog. We disclose that as performance obligations in our 10-Q; this ordering activity came in stronger than in either of the last couple of years, which is an encouraging signal for the remainder of the year. Turning to the X transition, it keeps moving along nicely. During Q1, about 68% of high-throughput gigabits shipped and roughly 43% of high throughput consumables revenue came from the NovaSeq X Series. More than 80% of high throughput gigabits shipped to customers in research markets already runs on NovaSeq X Series. And clinical volumes now exceed 50% on X as well. We keep advancing against the framework we laid out previously: in the latter half of 2025, roughly 50% of high throughput revenue and about 75% of Gb shipped should be on the NovaSeq X Series, supported by sustained strong growth in underlying sequencing volume and solid adoption of X. As time passes, the price drag from a smaller mix of 6K consumables diminishes, and a considerably bigger share of high Gb growth flows through to revenue growth. On sequencing activity: total sequencing Gb output on our connected high and mid-throughput instruments expanded by a rate exceeding 30% versus a year ago, with healthy growth from clinical and research customers alike. Revenue from sequencing instruments came in at $109 million, essentially unchanged compared with the same period a year earlier in Q1. We shipped more X Series instruments than anticipated in high throughput, and the MiSeq I100 launch in our low throughput portfolio went well. The shift toward clinical use of NovaSeq X is still underway, since roughly 60% of the X units placed during Q1 went to clinical customers. As you're aware, restrictions on our ability to export instruments into China began early in march; we held inventory inside the country that allowed us to fulfill our instrument orders during Q1. Sequencing service and other revenue reached $142 million, a decline of about 5% versus a year ago, which matched expectations, primarily because of how certain strategic partnership revenues tied to the AGD consortium fell last year. Setting those aside, our core services and informatics business expanded in the mid-single digits. Now turning to the remaining portions of Illumina's P&L. Non-GAAP gross margin for the first quarter was 67.4%, up 30 basis points from a year earlier. That margin came in a bit below what we had expected because instruments made up a larger share of the mix. Beyond that, we are currently deploying software upgrades across our high-throughput instruments, which is lifting their performance. Through this upgrade effort, we are additionally accelerating a portion of routine instrument service work, and the cost impact has been greater than we had modeled. We've asked that the bulk of these upgrades wrap up by Q2. Our manufacturing cost actions keep delivering solid progress. Non-GAAP operating expenses totaled $489 million. That figure mirrors our continued emphasis on cost optimization while investing in priority growth areas. During the quarter, we launched further measures aimed at cutting our full year expenses by $100 million and captured a partial benefit in Q1. With these cost reduction initiatives in place, we don't anticipate the usual seasonal increase in OpEx that follows Q1 will happen again in 2025, and we expect OpEx to be flat to slightly down across the rest of the year. The $100 million in cost actions to be realized in 2025 include certain stock-based compensation changes and amount to more than $225 million in total run rate reductions once fully annualized over the next 4 years. Non-GAAP operating margin was 20.4% in Q1. Turning to our results below the line. non-GAAP other expense, mostly made up of net interest expense, was $15 million, while the non-GAAP tax rate was 22%, and average diluted shares stood at approximately $159 million, $1 million below the prior quarter, driven by share repurchases, net of dilution from employee equity awards. Taken together, non-GAAP EPS of $0.97 per diluted share landed at the high end of our guidance range. Now on to cash flow and balance sheet items for the quarter. Cash flow provided by operations was a robust $240 million. Keep in mind that our annual cash bonus is paid out in Q1. Capital expenditures were $32 million, and free cash flow was $208 million. In Q1, we repurchased approximately 1.73 million shares of Illumina stock for $200 million at an average price of $115.74 per share. These repurchases were completed in February. At the close of the quarter, we held roughly $1.24 billion in cash, cash equivalents and short-term investments, alongside gross leverage of about 1.8x gross debt to last 12 months EBITDA. Turning now to our 2025 guidance. You've likely noticed in the press release that we're revising our guidance to account for how recent shifts in the geopolitical landscape have affected us. Our confidence stays high regarding the ongoing strength of our business and the underlying growth in sequencing demand. That said, the broader environment continues to be dynamic, so we're offering estimates of known changes as of today and incorporating those impacts into our guidance. When it comes to our China business, we'll now give guidance separately for the Greater China region. This provides visibility into how our business in China is evolving, as well as the fact that over 95% of our business in 2025 outside Greater China is making significant progress towards our long-term financial targets. Beginning with revenue. We are lowering our revenue guidance for Greater China by $125 million at the midpoint, tied to export restrictions on instruments and the projected impact on the remainder of our China business.

Ankur Dhingra

executive
#4

When it comes to the rest of the world, we're bringing our revenue guidance down to account for two things. First, there's a 2% to 4% reduction in revenue on a quarterly basis, weighted more heavily toward our research customers because of a constrained funding environment, and that's partially offset by the second item: roughly 1% of extra quarterly growth coming from clinical customers, since we've had strong instrument placements over the past couple of quarters. Combined, these 2 items have a net impact of about $60 million across the next 3 quarters. On top of that, we're implementing pricing actions that will deliver incremental revenue benefit mainly in the back half of the year. Relative to the guidance we gave earlier, favorable foreign exchange adds about $25 million to the revenue we expect to report. When you add all of that up for the rest of the world, the midpoint implies a 1% increase in revenue. Now on China: we're having ongoing conversations with the regulators about a long-term resolution. Our guidance reflects a pragmatic stance, and we've put expense measures in place so that the hit to our earnings is offset, both for this year and cumulatively as we move ahead. For the full year, our guidance in Greater China is between $165 million and $185 million in revenue. Q1 accounted for $72 million of that, and we're projecting $60 million in Q2 of '25, leaving just $43 million at the midpoint for the back half of the year. Should things resolve favorably in China, that would add upside beyond what we've guided. Turning now to our product assumptions. Outside Greater China, we're expecting sequencing consumables growth of flat to 2%, powered by solid sequencing activity, particularly among our clinical customers. On sequencing instruments, our assumption is that customers will keep managing their capital investments carefully. On the instrument side, we're looking at NovaSeq X demand holding fairly steady, with low-throughput growth coming from MiSeq i100 placements, and that product is getting a great reception. Outside Greater China, we anticipate sequencing instruments will be about level compared with last year. Turning to EPS: you'll remember that when we revised guidance in March, keeping EPS at roughly $4.50, we factored in lower revenue from the Greater China region, pressure from a tighter funding climate, and the new steps we began taking to safeguard earnings growth. With our updated EPS guidance, we've also accounted for what has happened since then, and the biggest thing weighing on that guidance is the new tariff situation. When it comes to Illumina, tariffs are expected to cost us roughly $85 million in gross terms for 2025. Most of that figure stems from products we ship into the United States out of our Singapore manufacturing site. The rest comes from parts and subassemblies brought into our U.S. manufacturing operations, plus Illumina products that get sold in China. As for Q2, inventory effects mean we'll only feel a portion of the hit during that period, with somewhere between $30 million and $35 million landing in the quarters that follow. The guidance we've put out there today does not incorporate any further tariffs, and it also doesn't include any retaliatory duties that might come from the EU or other regions. We're pursuing a number of steps spanning supply chain optimization, pricing, and other expense measures so that we can fully offset the hit from these tariffs. Those steps don't pay off overnight, and the extra benefit from them will show up in 2026; when it comes to 2025, we anticipate offsetting about half of the tariff impact, which is why we're taking the midpoint EPS down by $0.25 relative to the revised guidance we gave in early March. Beyond our continuing push to cut costs, we also intend to keep buying back stock through the share repurchase authorization we approved earlier, which had $1.2 billion left as of the quarter's end. The repurchases should give EPS a small lift this year from accretion. Our FY '25 EPS outlook includes about $0.35 attributable to Greater China. For FY '24, we figure Greater China EPS came in around $0.76. If you take the middle of our guidance, EPS from the rest of the world would be $3.90 this year — that's 15% growth against a roughly similar comparison from a year ago. Like I said before, the cost measures we started in March will produce added gains later on and drive earnings higher regardless of what happens in China. Pulling this all together, our updated guidance for the year puts revenue between $4.18 billion and $4.26 billion, which is a decline of 3% to 1%. And if you exclude Greater China, that's growth of flat to 2%. We anticipate a non-GAAP operating margin of about 21.5% to 22%, which is 45 basis points of expansion at the midpoint against 2024. The net effect of tariff-related items comes to a 125 basis point reduction in operating margin; on top of that, we're bringing down our non-GAAP tax rate, now projected at roughly 22%. All of this produces an EPS guidance range of $4.20 to $4.30. Turning now to the second quarter of 2025. For Q2, we anticipate total revenue of between $1.04 billion and $1.06 billion; that figure includes Greater China region revenue of between $55 million and $65 million, plus revenue outside the Greater China region ranging from $980 million to $1 billion, or a year-over-year decline of between 2% and 3%, mainly because of a drop in certain strategic partnership revenues along with the research market dynamics I've described; since we're only applying the pricing actions to new orders, the benefit in Q2 will be minimal. For our non-GAAP operating margin, we're looking at roughly 21%, and non-GAAP EPS should land somewhere between $1 and $1.04. Those numbers both include the roughly $15 million hit we expect tariffs to have on direct costs. Just like the guidance we gave before, this points to half 2 contributing more than half 1, and that depends on consumables growth continuing to get better as X makes its transition, plus the impact of the cost and pricing moves we just set in motion, which build momentum during half 2. Before I close, I'd like to acknowledge the perseverance and commitment every Illumina employee has demonstrated through a situation that only keeps getting more volatile. My confidence stays strong regarding the road ahead, as well as the capacity of the Illumina team to deliver against the financial targets we have set for both the near term and the long term. Thanks for being with us on today's call. At this point I'll ask the operator to open the line so we can take questions.

Doug Schenkel

analyst
#5

On a basic level, putting money into Illumina right now means you have to believe that the top line will begin turning around before too long — ideally in the coming year — and that profitability will rise above 25%. You're taking every step available to keep expenses in check. That deserves praise. I'd say the bulk of the uncertainty at this moment concerns the outlook for top line growth. You've already given us plenty of help on that front. But if — I'm hoping you could assist us along a few lines; so for the quarter, excluding China, how much did total clinical revenue grow? And how much did total research grow? Then, extending from that, when we consider the full-year guidance, what assumptions are you making for each end market? It appears you may be modeling a double-digit contraction in the research end market while still assuming mid-single-digit or better expansion on the clinical side? And finally, regarding China, per your guidance it will fall to 4% of sales, a sharp drop from 10% 2 years ago. Even so, should 4% decline further in the next year, that could still act as a drag during a stretch when we're all hoping conditions begin to get better. Are there additional measures you're weighing to address that exposure as we look at not only 2025, but past it?

Jacob Thaysen

executive
#6

Thank you, Doug. There were definitely several questions there. So allow me to begin, and I'm certain Ankur will also need to assist me in recalling all of the questions. But above all, we see a business that is very resilient. I believe Illumina has demonstrated across the recent stretch that even amid very strong headwinds, we can still actually keep a great deal of activity going out there. There's substantial sequencing activity, which forms part of the underlying rationale for returning to high single-digit growth that we expect to enter into across the coming years. There's nothing — from that angle, beyond China, we aren't observing any major shift strategically versus what we shared with you earlier this summer, which centers entirely on moving to the X, and because of that, as we make that move, we'll find that the volume present in the market converts more substantially into revenue growth. And we are entering this in '25, where we have — where we remain on course to deliver no less than 50% of revenue on the X, on high throughput on the X, by the second half of this year, and afterward we'll see the revenue follow; so our confidence there remains solid. We do think our strategic framework is still intact, and at present we're referring to ex China since we'll watch how China develops. You're completely correct that in '25, we're going to land around 5% if circumstances in China stay as they are right now. And clearly, we anticipate an additional drop as we move into '26 absent any shift; however, it's also worth pointing out that the cost measures we implemented a few weeks back carry a $100 million effect this year, yet as Ankur noted too, they'll deliver a fully examined total worth exceeding $200 million across the coming years; and because of that, we've taken these steps so they entirely offset whatever takes place in China during the period ahead. So I believe that matters. And as a result, we likewise view the $4.25 EPS as our fresh baseline from which to expand, guided by our strategic framework running from double-digit to teens growth. So I'd like to open simply by reaffirming our strategy. Yet clearly, at this moment, we're focused on the ex China operation, which represents 95% of what we do; so Ankur, perhaps you could share a bit more perspective regarding what we've projected from a growth rate standpoint.

Ankur Dhingra

executive
#7

Absolutely, Doug — I’ll take on the research versus clinical topic, covering both the short term and what’s included in the guidance, and so on. So when you consider Q1, with everything going on, we all recognize the shifts that have occurred in the geopolitical landscape. If you compare our clinical segment with our research segment in Q1, the clinical side has kept showing its momentum — we’ve mentioned the really robust X placements that rolled over from Q4 into Q1. Looking at our consumables within clinical, that business rose mid-single digits; and, as you’re aware from the specifics in our guide, we have raised our outlook for the clinical business for the balance of the year, since we keep seeing quite healthy demand. We keep seeing really solid uptake for the tests already being sold, plus the newer ones we expect will reach the market during the back half of the year. On the research side, which has faced tougher conditions over the past few months, our research business declined — I mean consumables — in the mid- to high single-digit range; and when we consider the rest of the year, since the shifts in the research climate began at some point around the middle of the quarter, as we think ahead and as we reflect on the discussions we’ve had with our research customers, particularly in academia, the government side has more difficulties due to 2 factors: first, their funding situation is tight. And second, because of tariffs, there will be some inflationary pressure arriving from various directions. So that combined effect will persist throughout the year; therefore we’ve reduced our expectations for the research market for the remaining portion of the year. Our guidance now assumes a mid-double digit, roughly near 15-ish percent drop, particularly in that ANG space for the rest of the year; so greater than what we saw in Q1, both from the full-quarter effect and from some of the extra impacts that, that business will experience; so clinical is stronger, but yes, research, we expect it to be weaker.

David Westenberg

analyst
#8

I'd like to dig into the consumables picture for mid-throughput and low-throughput. My guess is there could be 1 of perhaps 3 explanations: either a shift toward X, whether directly or via a service provider, some form of competitive pressure, or possibly just insufficient funding? There may be additional factors at play, but I'd figure those are the 3. Could you put some percentage figures around which of these is actually occurring — and I'm framing this around elasticity absorption when I compare that first factor with the second one, which is clearly the more negative scenario. And the third factor, of course, is shutdowns, which could be temporary because of funding. So it would be helpful to hear whether you can attach numbers to that? Then a very quick point regarding how conservative the guide is here. Ankur, I think you mentioned having additional commitments from customers, something like a contractual commitment. I just want to check whether I heard that right, since it would give us some reassurance about the guide. I believe that's what you said — I just want to verify you did in fact say it.

Jacob Thaysen

executive
#9

Yes. Thanks, Dave. I'll begin with the broader market picture for mid- and low throughput. First and foremost, we're extremely enthusiastic about the MiSeq i100, which we introduced in very late last year, and momentum in that market keeps building. So that has us very excited. The MiSeq i100 has gotten a very positive reception, we keep seeing considerable interest, and our order book for the MiSeq i100 is very strong. So on low throughput, we're really enthusiastic, with substantial momentum right now. On mid throughput — and we've discussed this over, I'd almost say, the entire time since I arrived — overall, what we've observed is that when market conditions are difficult, this segment faces more difficulty than high throughput. The explanation is that mid throughput is less of a production setting and more of a setting involving another research segment or a small, you might say, clinical account that may lack the volume needed to fill a high-throughput system, and as a result it isn't utilized at the same level or with the same rigor you find in high throughput, which follows small and manufacturing kind of logic; so consequently, you also observe that when this environment has constraints, this is where an acquisition or purchase of an extra instrument may get pushed out, or you may actually choose to move to a service provider, where we still capture the reagent and consumables flow. So the big-picture takeaway hasn't changed from what we've said previously: that's exactly why this particular market is tighter overall than the high throughput one. Another thing to keep in mind is that we introduced the XLEAP chemistry roughly 12 months back, and we're witnessing a great deal of adoption. A large portion of our customer base has moved over to the XLEAP chemistry, since it's an improved chemistry and delivers more — a more attractive price point for customers, but just as importantly, top quality, and it actually gives greater capacity with the sequencer; so naturally, we're also working through price rebalancing in this area. So I'd say those represent the 2 primary factors behind the softness in the mid-throughput space. Admittedly, there's greater competition here as well. I believe I brought that up earlier; and naturally, particularly in China, where competition has been intense, clearly, given the circumstances we face in China. That's obviously a significant weak spot for us at the moment, at least when it comes to instrument placements. Conversely, I'd note that based on what I can tell from the research that's been published, we've actually done quite well in China compared with our nearest competitor there. So on the whole, it's a difficult environment, but I believe it's far more macro-driven than it is a matter of competition. I think there was another question, perhaps Ankur can go into more detail.

Ankur Dhingra

executive
#10

Now, regarding how we handle performance obligations and the way our backlog gets built up. Let me give you some context on that, since Q1 typically carries a seasonal pattern, and Illumina tends to see a pretty — this is the period when many of our longer-term contract discussions and renewals take place. That figure gets disclosed as performance applications in our 10-Q. So I'd encourage you to check that out. What I'd add on that point is that for this year, those order bookings, the long-range order bookings, have increased quite substantially. In fact, our performance obligations have risen by double digits compared to a year ago and have improved far more than what we experienced over the prior couple of years.

Jack Meehan

analyst
#11

Jacob, Ankur, given what's happening with tariffs in the market right now, do you think that could have played a role in any of the demand during the first quarter? And then, I'm not sure whether you'd be open to saying anything about the period since Liberation Day — purely from a demand standpoint, have the tariffs that were announced affected how customers purchase at all?

Jacob Thaysen

executive
#12

Thanks, Jack. What I'd tell you is that for Q1, nothing stood out — we didn't observe any particular shift or change in customer behavior tied to the tariff circumstances. And my sense is we haven't seen that in Q2 either; there has been a bit of pull-in in China, I believe out of worry over what might unfold in China; but as far as the rest of the world goes, nothing material seems to be showing up. So it hasn't factored into how the quarter progressed.

Ankur Dhingra

executive
#13

Still, as you're aware, I should mention that at minimum through the remainder of this year, we fully expect that once the tariff effect is more clearly understood and begins appearing in costs, some effect will be felt, and we have therefore lowered our guidance.

Vijay Kumar

analyst
#14

Ankur, Jacob, if you don't mind, just one question about the assumptions behind the revenue guidance. Previously, guidance called for an increase in the low singles. As I understand it, the updated guidance now points to a decline in the low singles, which is a swing of maybe 300, 400 basis points. Yet when I examine what changed in the China assumption, it seems nearly the entire revision came from reducing China. So I'm not sure where the research — Ankur, when you mentioned research, you said it's resuming down 15%, how is that being factored in, and what about the offset, is clinical really, did that shift relative to what was assumed before? If research did change, where is the offset coming from?

Jacob Thaysen

executive
#15

Yes, I'll begin and then have Ankur again go deeper into the numbers here; but broadly, when we issued our March forecast, we had already anticipated that there would be an impact both from China and from the NIH funding; so that was already incorporated; so those were the overall expectations within it. Clearly, at that moment, we stated that there were various outcomes we had been expecting. And so now we're giving the full details of this. Broadly, that's the high-level direction we're taking. We feel we have a good sense for now where the academic and government is going; and as Ankur was mentioning, at this point, we are expecting that it will continue with a 15% decrease, and that's the main driver for it. Conversely, we see actually that our clinical customers are showing up stronger here in Q1. So we anticipate and we're seeing that in our numbers also that the clinical business is more robust and stronger than — and we're really pleased with that right now.

Ankur Dhingra

executive
#16

Yes. Vijay, at a high level, to give a bit more color: indeed, the largest portion of the shift sits in China, which we've now broken out separately. As for the rest of the world, the pluses and minuses are that research has declined. We mentioned approximately — taking a midpoint, roughly 3 percentage points; and I'm only referring to the remaining 3 quarters; so annualization will land wherever it lands, but about 3 points lower, which comes to approximately $90 million, so to speak, from the research and tariff-related effect. Clinical is coming in stronger, both regarding our ongoing X placements and the units we expect will come live. So clinical delivers approximately 1 point of offset. And then we've discussed — talked about mitigating actions tied to tariffs, and part of that involves certain pricing moves. And I expect roughly 1 point of contribution from that too. So that's largely the pluses and minuses. There's also a minor piece from FX, which compared with our prior guide has turned less unfavorable. So from one guide to the next, it's now more favorable, and that contributes about 0.5 point to reported growth, not in constant currency, but on the reported side.

Tycho Peterson

analyst
#17

Ankur, I'd like to put your pricing assumptions under some pressure here. Sounds promising. I'm just wondering which parts of the portfolio you believe can bear a price increase. Clearly, you face rivals, and one of them is handing out sequencing at no charge. So could you speak briefly about how confident you are that you can genuinely begin moving pricing upward?

Jacob Thaysen

executive
#18

Sure. Let me begin with that, and afterward Ankur can add further specifics as well. Broadly speaking, Illumina has a lengthy track record, naturally, of steadily reducing prices, and naturally we'll keep making sure our customers receive competitive rates, and we're able to support competitive rates. Yet at the same time, in circumstances like these, you also want to — and the customer prefers dealing with businesses that will still exist years down the road. And so we take a careful stance toward our pricing approach and, naturally, toward how we can go out and deliver truly inventive projects to our — inventive offerings to our customers. So we sense, and given this tariff situation emerging, clearly, we'd be delighted to offset it to the greatest extent we can, and we're actively working to offset it to the greatest extent we can so our customers feel the smallest possible impact; yet right now, as you're also able to observe, we do have — we're confident it was the right call, and we performed extensive analysis, examining what figure and what amount we could include. And clearly, no one welcomes a price hike. I mean, I don't personally care for it, and no customer will care for it either. So we acknowledge this has — an effect on our customers, yet we're optimistic that we'll manage and that our customers will grasp that Illumina is built for the long haul; so if you partner with us and we push through this difficult period together, we'll reach the other side and keep delivering innovations to our customers and helping them succeed. If you decide to hand out your sequencing for nothing, I can promise you won't have a business within a few quarters.

Conor McNamara

analyst
#19

Thanks for the thorough details regarding how tariffs are affecting things — I genuinely appreciate it. To broaden the discussion slightly on the rivalry side: have you noticed buyers holding off or pushing back equipment orders because they expect something current or upcoming from your competitors?

Jacob Thaysen

executive
#20

Yeah. That's a terrific question. We've actually encountered this a handful of occasions already — we remain in a highly contested arena; honestly, we believe our performance versus rivals is strong. Yet, as everyone is aware, a fresh statement surfaced roughly several weeks back, something I'd describe as a technology overview; no product was launched. With any technology overview, generating excitement is simple. Keeping customers happy is extremely hard. So at this moment, there's a bit of buzz surrounding it. Anyone can stand up and pledge all sorts of things. Ultimately, though, what matters is that daily, you must prove yourself over and over. And particularly when conditions are rough, buyers gravitate toward an organization capable of supplying — one where delivery commitments are dependable, and additionally where we ensure success whether you're a clinical client or a research client. That gives us strong confidence. Still, up to now, we haven't observed any interruption from customers who postponed choices because of possible technology whose specifics, honestly, remain unknown to us; I doubt our customers fully understand what that emerging technology entails either. It's an entirely new technology; demonstrating it requires time — every technology must pass through the — essentially the — validation via academic research, yet they'll proceed, they'll produce some — their paper, they'll conduct their analysis, their research regarding it, and that takes time. Technologies come with all sorts of complications; this isn't a simple field. This isn't a developed market and time will be needed; so we'll monitor developments, though currently, nothing has changed.

Michael Ryskin

analyst
#21

A big chunk of this call has been about China — what's different there, and how you see that market for the remainder of the year. You brought up academic and government headwinds for this year. How should we think about those two markets as we head into 2026? What I'm getting at is, if you're doing $15 million, $20 million, $25 million per quarter in China in 3Q, 4Q, does that drop to 0 in 2026? Or is that a level you think can be sustained, and maybe you start growing from there again? And the same question on A&G — looking at what's going on in the U.S., with NIH and so on, it doesn't look like a temporary headwind. Stepping back and looking at next year and the year after, these are 2 pivotal markets. After the headwinds this year, where do you see them going from here?

Jacob Thaysen

executive
#22

Yes. Thanks, Mike. And I'm with you that we're spending far too much time discussing China, which accounts for 5% of our business, and we're probably also devoting far too much time to certain headwinds in NIH, when we have very strong markets still growing robustly, particularly in the clinical market. And incidentally, in Europe, which remains a very, very strong performer for us. So I agree, we're spending — every one of us is spending far too much on a very small portion of our business; and we're a very resilient business that keeps driving a lot of activity out there and producing fantastic cash flow; so let's begin there. China, as Ankur mentioned, we're working, naturally, with the Chinese authorities to determine whether a solution can be found. But we've taken the access right now. that if we aren't able to have a long-term sustainable business in China, we'll still be able to offset that through the cost measures we're taking. We are — as you can see in our numbers, we currently expect the China business to keep declining in revenue over in the second half of the year; and if nothing changes in our conversations with the regulators there, naturally, it will keep shrinking in '26. But we remain very hopeful. We believe China is an important market. And we — I had the chance here last week to actually — to spend time with some of our Chinese colleagues. And it's very clear that the Chinese customers truly want us to stay in this market. And we truly want to help them keep being successful; so we don't know at this point, but we're doing everything we can to rectify the situation; but if not, we've taken the cost structure to do so. Alright, regarding academia and government — sure, there are some challenges we're facing at the moment. I genuinely think that everyone will — a lot of politicians, in the U.S. as well as across the globe, recognize that research done in academia plays a critical role in pushing the industry ahead, and not just academic research, but obviously, it serves as the pipeline into pharma and, naturally, into medical science as a whole. So my belief is that this challenge is near-term or only temporary, and we'll emerge from it in a stronger position. After all, the 21st century is biology's century, and what we're seeing is just a small bump, and going forward we'll see robust results in this area.

Kyle Mikson

analyst
#23

Turning to the GRAIL probe from not long ago — it appears the SEC is about to wrap that up. Should that occur, would it hand you greater latitude to pursue bigger acquisitions or transactions involving the purchase of clinical labs that carry sizable market opportunities, like MRD? Then, stepping back, that divestiture happened nearly 12 months ago. Has it genuinely assisted you in speeding up core Illumina? On the face of it, perhaps not, judging by the performance, yet your focus on the pipeline is stronger at present. So I would really like to hear what you think about all that.

Brian Blanchett

executive
#24

Kyle, apologies — we couldn't catch the latter portion of what you asked?

Kyle Mikson

analyst
#25

It's been close to 12 months now since the divestiture happened. Has it truly allowed you to speed up what Illumina does at its core?

Jacob Thaysen

executive
#26

Yeah. Let me begin with the first point, which is that obviously we're quite happy the SEC investigation has wrapped up with no findings — something we had anticipated as well. So having that matter resolved feels good. Naturally, we keep evaluating chances for value-added bolt-on acquisitions, and we're still watching the space. That said, we're quite disciplined about where we think opportunities exist, though we're also producing substantial cash annually, which gives us room to consider various options. I believe I can state with confidence that MRD probably isn't an area we'll be pursuing at this point. Ankur?

Ankur Dhingra

executive
#27

Absolutely, and I appreciate you bringing that up, Jacob. Our balance sheet is in a really strong spot, and we're quite happy with the cash flow we've been producing — it's now been 3 quarters since GRAIL. We've brought in more than $1 billion of cash. I was also really happy with how Q1 turned out, because even with the research market being where it was, and even though we paid out annual bonuses during that quarter, we still brought in more than $200 million in cash. So that's very satisfying and leaves us in an extremely strong position. As you're aware, we've also repurchased about $200 million in shares over the quarter. That said, growth and bolt-on M&A stay our top priority. There are a number of technologies out there that we believe could benefit from our size, our scale, and our large installed base — that's really where we're concentrating. And hopefully, we'll find some that we can actually act on. At the same time, like we've mentioned, we don't plan to just sit on cash indefinitely; and as I said in my script, throughout the remainder of the year, we'll keep repurchasing shares opportunistically as well.

Jacob Thaysen

executive
#28

Let me be clear about what I said regarding MRD. In my view, MRD presents a very large opportunity — it's just that Illumina wouldn't be pursuing it through M&A.

Marta Nazarovets

analyst
#29

This is Marta speaking on behalf of Rachel. Regarding the mitigation steps for tariffs that you mentioned, could you share which ones are already in place and which remain to be done? Then, what effect do you anticipate that having on your EPS pacing through the remainder of the year? Also, one brief clarification: at this stage, are you factoring in any 4Q budget flush?

Jacob Thaysen

executive
#30

Yes; from a tariff standpoint, clearly, this has only been — though it feels like quite a while, it's merely been a handful of weeks since we have — every one of us has wrapped our minds around what the tariff situation looks like. And naturally, it remains a movie still being shown. So naturally, it is a flexible or it is a target that keeps moving at present. But as far — based on what we can observe now, and I believe that's what we're also noting, our present expectation is that the effect for 2025 here will come to roughly $85 million and that we can offset roughly half of it. Mostly — we are both examining altering certain parts of our supply chains. Clearly, we're collaborating with many of our suppliers themselves, but also considering where we manufacture; we have — the bulk of our manufacturing takes place either in Singapore and U.S., and we actually — and that's established, it can be optimized, yet at this moment, we aren't aiming to make major alterations to that footprint. However, we have already gone out and taken steps on the pricing side as well. And so we feel confident about the steps we've taken so far, and we will keep optimizing our footprint moving forward in our supply chain.

Brian Blanchett

executive
#31

Excellent. We appreciate your presence with us on this occasion. A recording of today's discussion can be accessed under the Investors portion of our site; that brings this call to an end, and we anticipate meeting you at the events we have coming up. Thanks.

Operator

operator
#32

Once more, everyone, that brings us to the end of today's call. We appreciate your taking part. At this point you're free to hang up, and enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.